Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Public ClinicalTrials.gov record NCT00048945. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
Study identification
- NCT ID
- NCT00048945
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 820 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2002 (Actual)
- Primary completion
- Oct 2004 (Actual)
- Completion
- Oct 2004 (Actual)
- Last update posted
- Feb 17, 2017
2002 – 2004
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | 85259 | — |
| Not listed | Downey | California | 90242 | — |
| Not listed | Los Angeles | California | 90048 | — |
| Not listed | Pasadena | California | 91105 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Honolulu | Hawaii | 96817 | — |
| Not listed | Boston | Massachusetts | 02111 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Not listed | Minneapolis | Minnesota | 55404-4565 | — |
| Not listed | Lincoln | Nebraska | 68501 | — |
| Not listed | Chapel Hill | North Carolina | 27599-7080 | — |
| Not listed | Cedar Creek | Texas | 78612 | — |
| Not listed | Salt Lake City | Utah | 84121 | — |
| Not listed | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00048945, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2017 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00048945 live on ClinicalTrials.gov.